Effect of Lactobacillus delbrueckii subsp. lactis on vaginal radiotherapy for gynecological cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 06 2023
21 06 2023
Historique:
received:
07
11
2022
accepted:
19
06
2023
medline:
23
6
2023
pubmed:
22
6
2023
entrez:
21
6
2023
Statut:
epublish
Résumé
The aim of this study was to evaluate the effect of Lactobacillus delbrueckii subsp. lactis (L.del) on vaginal microbiota (VM) dysbiosis and vaginal radiation injury in gynecologic cancer patients. The inhibitory effects of L.del on cervical cancer cells were also studied in vitro. Gynecologic cancer patients receiving radiotherapy were randomized into control and L.del intervention groups. The control group received radiotherapy, while the intervention group received radiotherapy and L.del intervention (1 capsule/day placed into the deep vagina from the first day of radiotherapy until the end of treatment). Vaginal swab samples were collected on the first day pre-treatment and the last day post-treatment. DNA from 54 patients was extracted and assessed by the 16S rRNA sequencing method. Radiotherapy resulted in vaginal microbiome dysbiosis characterized by increased phylogenetic diversity and increased abundance of Brevundimonas, Streptococcus and Prevotella, but a decreased abundance of Lactobacillus. Level 2 vaginal radiation injury was positively associated with the abundance of Brevundimonas and gram-negative non-fermenting bacteria. Administration of L.del attenuated the reduction of Lactobacillus while also inhibiting the abundance of Streptococcus and Prevotella, thereby ameliorating radiotherapy-related vaginal microbiota dysbiosis. CLD inhibited the in vitro proliferation of SiHa cells by altering the expression of BCL2, HPV16-E6, HPV16-E7, IL6, MAP7, BAX, Caspase-3, Caspase-9 and LTF. In conclusion, L. del application can alleviate radiation-induced vaginal dysbiosis and restore Lactobacillus dominance of the vaginal microbiome. Moreover, CLD was found to inhibit cell growth and promote the apoptosis of SiHa cells in vitro. The registration number for this clinical trial is ChiCTR1900021784.
Identifiants
pubmed: 37344615
doi: 10.1038/s41598-023-37241-7
pii: 10.1038/s41598-023-37241-7
pmc: PMC10284825
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Banques de données
ChiCTR
['ChiCTR1900021784']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10105Informations de copyright
© 2023. The Author(s).
Références
Cancer Med. 2020 Jun;9(11):3714-3724
pubmed: 32237205
Cell Host Microbe. 2018 Feb 14;23(2):159-168
pubmed: 29447695
Oncogene. 2013 Sep 5;32(36):4273-83
pubmed: 23069661
Eur J Clin Microbiol Infect Dis. 2015 Dec;34(12):2367-76
pubmed: 26385347
Front Cell Infect Microbiol. 2020 Dec 07;10:538336
pubmed: 33365275
Med Dosw Mikrobiol. 2005;57(1):7-17
pubmed: 16130291
Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4680-7
pubmed: 20534435
Gynecol Oncol. 2021 Feb;160(2):602-609
pubmed: 33303211
J Biol Chem. 1999 Jan 22;274(4):2225-33
pubmed: 9890985
J Physiol. 2017 Jan 15;595(2):451-463
pubmed: 27373840
J Appl Microbiol. 1998 Jan;84(1):81-9
pubmed: 15244061
Biomed Res Int. 2013;2013:123241
pubmed: 23586015
Nutrients. 2019 Oct 01;11(10):
pubmed: 31581434
Nat Med. 2019 Oct;25(10):1500-1504
pubmed: 31591599
Bioinformatics. 2015 Sep 1;31(17):2882-4
pubmed: 25957349
Lancet. 2010 Mar 6;375(9717):816-23
pubmed: 20206777
Braz J Microbiol. 2015 Jun 01;46(2):455-64
pubmed: 26273260
Cancer. 2019 Apr 1;125(7):1081-1090
pubmed: 30521105
Cancer Cell Int. 2020 Jul 29;20:354
pubmed: 32760221
Genes Dev. 2001 Nov 15;15(22):2922-33
pubmed: 11711427
PLoS One. 2013 May 22;8(5):e63514
pubmed: 23717441
Am J Obstet Gynecol. 2001 Aug;185(2):375-9
pubmed: 11518895
Cell Mol Life Sci. 2019 Feb;76(3):473-493
pubmed: 30317530
Ceska Gynekol. 2018 Winter;83(5):371-379
pubmed: 30848142
Front Cell Infect Microbiol. 2022 Sep 21;12:1006723
pubmed: 36262183
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Int J Biol Macromol. 2018 Jun;112:203-206
pubmed: 29391223
Front Med (Lausanne). 2018 Jun 13;5:181
pubmed: 29951482
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2021 Apr 8;11(1):7693
pubmed: 33833301
PLoS One. 2010 Jan 27;5(1):e8694
pubmed: 20111700
Biometals. 2010 Jun;23(3):507-14
pubmed: 20411301
Acta Microbiol Immunol Hung. 2022 Mar 17;:
pubmed: 35298410
J Contemp Brachytherapy. 2018 Dec;10(6):559-566
pubmed: 30662479
Front Cell Infect Microbiol. 2022 Jun 21;12:814668
pubmed: 35800384
Biofouling. 2013;29(1):53-68
pubmed: 23194413
Immunity. 2015 May 19;42(5):965-76
pubmed: 25992865
Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:25-32
pubmed: 34144490
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Nat Rev Urol. 2020 Apr;17(4):232-250
pubmed: 32071434
Mol Biotechnol. 2012 Jan;50(1):62-71
pubmed: 21611910
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
PLoS One. 2016 Apr 26;11(4):e0153274
pubmed: 27115350
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Arch Oral Biol. 2011 Nov;56(11):1282-9
pubmed: 21616477
Cells. 2020 Dec 25;10(1):
pubmed: 33375694
Front Cell Infect Microbiol. 2021 Oct 27;11:680038
pubmed: 34778097
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
Eur J Clin Microbiol Infect Dis. 2014 Mar;33(3):291-304
pubmed: 24057141
Cancer Cell Int. 2020 Jan 13;20:17
pubmed: 31956295
Microb Ecol. 2013 Apr;65(3):773-80
pubmed: 23250116
Nagoya J Med Sci. 2018 Nov;80(4):487-496
pubmed: 30587863
Lancet Oncol. 2003 Sep;4(9):529-36
pubmed: 12965273
N Engl J Med. 2016 Dec 15;375(24):2369-2379
pubmed: 27974040
Sci Transl Med. 2017 Nov 15;9(416):
pubmed: 29141885